KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Evolent Health (EVH) EBIT (2016 - 2025)

Evolent Health (EVH) has 11 years of EBIT data on record, last reported at -$408.2 million in Q4 2025.

  • For Q4 2025, EBIT fell 2095.26% year-over-year to -$408.2 million; the TTM value through Dec 2025 reached -$410.1 million, down 913.06%, while the annual FY2025 figure was -$410.1 million, 913.06% down from the prior year.
  • EBIT reached -$408.2 million in Q4 2025 per EVH's latest filing, down from $886000.0 in the prior quarter.
  • Across five years, EBIT topped out at $13.0 million in Q3 2022 and bottomed at -$408.2 million in Q4 2025.
  • Average EBIT over 5 years is -$36.6 million, with a median of -$11.3 million recorded in 2021.
  • Peak YoY movement for EBIT: surged 296.79% in 2022, then tumbled 2095.26% in 2025.
  • A 5-year view of EBIT shows it stood at -$12.2 million in 2021, then surged by 84.62% to -$1.9 million in 2022, then crashed by 1036.85% to -$21.3 million in 2023, then increased by 12.9% to -$18.6 million in 2024, then crashed by 2095.26% to -$408.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT were -$408.2 million in Q4 2025, $886000.0 in Q3 2025, and -$1.2 million in Q2 2025.